Literature DB >> 26136914

Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review.

John T Denny1, Andrew T Burr1, Fred Balzer2, James T Tse1, Julia E Denny3, Darrick Chyu1.   

Abstract

Rabbit anti-thymocyte globulin (rATG) is an infusion of polyclonal rabbit-derived antibodies against human thymocyte markers, which can be used to prevent and treat acute rejection following organ transplantation. However, the product monograph issued by the manufacturer (Sanofi Canada) reports that serious immune-mediated reactions have been observed following the use of rATG, consisting of anaphylaxis or severe cytokine release syndrome (CRS), which is a form of vasoplegic syndrome (VS), in which distributive shock occurs refractory to norepinephrine (NE) and vasopressin (VP). Severe infusion-associated reactions are consistent with CRS and can cause serious cardiac or respiratory problems, or in certain cases, mortality. CRS is a form of systemic inflammatory response syndrome (SIRS). In SIRS, the substantial activation of endothelial inducible nitric oxide synthase (iNOS) and smooth muscle guanylate cyclase (GC) is observed, which can produce severe hypotension that is unresponsive to conventional vasopressors. Methylene blue (MB) is a direct inhibitor of iNOS and GC and has been used as an effective treatment for VS following cardiothoracic surgery. In the present study, the successful use of MB as a rescue therapy for CRS in a patient receiving rATG following a renal transplant was reported. Following an uneventful cadaveric kidney transplant involving the intravenous (IV) administration of rATG for the induction of immunological tolerance, the patient became markedly hypotensive and tachycardic. The patient required high doses of VP and NE infusions. Following the protocol described for treating refractory VS in post-cardiac surgery patients, the decision was made to initiate the patient on an IV MB infusion. This treatment protocol was shown to improve the hemodynamic status of the patient, which enabled the withdrawal of vasopressors and suggests an important role for methylene blue in the management of refractory VS.

Entities:  

Keywords:  cytokine release syndrome; cytokines; distributive shock; rabbit anti-thymocyte globulin; renal transplant complications; shock; thymoglobulin; vasoplegia; vasoplegic shock; vasoplegic syndrome

Year:  2015        PMID: 26136914      PMCID: PMC4471690          DOI: 10.3892/etm.2015.2349

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  41 in total

Review 1.  The pathogenesis of vasodilatory shock.

Authors:  D W Landry; J A Oliver
Journal:  N Engl J Med       Date:  2001-08-23       Impact factor: 91.245

Review 2.  Release of vasoactive substances during cardiopulmonary bypass.

Authors:  S W Downing; L H Edmunds
Journal:  Ann Thorac Surg       Date:  1992-12       Impact factor: 4.330

Review 3.  Anaphylaxis: a review of causes and mechanisms.

Authors:  Stephen F Kemp; Richard F Lockey
Journal:  J Allergy Clin Immunol       Date:  2002-09       Impact factor: 10.793

4.  The use of methylene blue for vasodilatory shock in a pediatric lung transplant patient.

Authors:  Brigid C Flynn; Robert N Sladen
Journal:  J Cardiothorac Vasc Anesth       Date:  2009-02-13       Impact factor: 2.628

Review 5.  Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response.

Authors:  E M Boyle; T H Pohlman; M C Johnson; E D Verrier
Journal:  Ann Thorac Surg       Date:  1997-01       Impact factor: 4.330

Review 6.  Vasoplegic syndrome--the role of methylene blue.

Authors:  Ganesh Shanmugam
Journal:  Eur J Cardiothorac Surg       Date:  2005-09-06       Impact factor: 4.191

7.  Anaphylactic shock depends on PI3K and eNOS-derived NO.

Authors:  Anje Cauwels; Ben Janssen; Emmanuel Buys; Patrick Sips; Peter Brouckaert
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 8.  General aspects of cytokine-release syndrome: timing and incidence of symptoms.

Authors:  D R Jeyarajah; J R Thistlethwaite
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

9.  Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery.

Authors:  E B Rosenzweig; T J Starc; J M Chen; S Cullinane; D M Timchak; W M Gersony; D W Landry; M E Galantowicz
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

Review 10.  Role of platelet-activating factor in cardiovascular pathophysiology.

Authors:  G Montrucchio; G Alloatti; G Camussi
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

View more
  2 in total

1.  Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.

Authors:  T Oura; K Hotta; J Lei; J Markmann; I Rosales; A Dehnadi; K Kawai; D Ndishabandi; R-N Smith; A B Cosimi; T Kawai
Journal:  Am J Transplant       Date:  2016-09-06       Impact factor: 8.086

2.  Antithymocyte globulin-induced refractory hypotension in renal transplantation recipient.

Authors:  Shamim Rafat; Sahu Sandeep; Siddiqui Tasneem; Agarwal Sanjay
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2017 Jul-Sep
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.